Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.

  title={Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.},
  author={Ylva B{\"o}ttiger and Philippe Dostert and Margherita Strolin Benedetti and Massimo Bani and Francesca Fiorentini and Marco Casati and I Poggesti and Christina Alm and Gunnar Alv{\'a}n and Leif Bertilsson},
  journal={British journal of clinical pharmacology},
  volume={42 6},
1. Nicergoline, an ergot derivative previously used as a vasodilator, has gained a new indication in treating the symptoms of senile dementia. 2. Nicergoline is rapidly hydrolysed to an alcohol derivative, 1-methyl-10-alpha-methoxy-9,10-dihydrolysergol (MMDL), which is further N-demethylated to form 10-alpha-methoxy-9,10-dihydrolysergol (MDL). A few individuals display aberrant metabolism of this drug, as shown by their diminished capacity to form the MDL metabolite. The aim of this study was… CONTINUE READING